Abstract:When elephants fight, it is the grass that suffers. —African proverb The foundational strategy for preventing cardiovascular disease (CVD) and recurrent cardiovascular events consists of lowering levels of low-density lipoprotein cholesterol (LDL-C), controlling blood pressure, and preventing and treating diabetes mellitus, combined with smoking avoidance and cessation, a healthy diet, and regular exercise. Despite decades of global progress in implementing risk factor reduction, progress has plateaued, and a recent uptick in risk has been observed in many areas characterized by lower income and lower levels of education. 1 In the United States, a significant increase in cardiometabolic disease resulting from the erosion of gains in modifying common risk factors has combined with opioid overdose and rising suicide rates to drive a downward trajectory in average life expectancy for 4 years in a row. 2 I approach this topic with significant conflicts of interest. As a former Commissioner of the US Food and Drug Administration, I have regulated LDL-C–lowering drugs. I have also conducted clinical trials, advised pharmaceutical companies, practiced cardiovascular medicine, and served as an institutional official for a large academic medical center and its health system, and I currently work for a company with an interest in the prevention and treatment of CVD. Therefore, my views and comments on the issue should be considered in light of these interactions, prior expressed beliefs, and financial conflicts. Although dietary and behavioral approaches to lowering LDL-C should be attempted, the results are modest and, for a majority of patients over longer intervals, only partly sustainable despite behavioral intervention. The use of statins, a class of drug that prevents the production of cholesterol by the liver, substantially reduces LDL-C and cardiovascular events, including death, stroke, myocardial infarction, and other sequelae of vascular disease. However, during the first decade that statins were broadly available, substantial cynicism directed toward the drugs fueled uncertainty that ultimately limited their use in clinical practice. Analyses show reduced use of statins and associated increases in cardiovascular events and death in countries when negative reports about statins appeared in popular media. 3 Statins eventually achieved blockbuster status after multiple blinded randomized trials conducted in large populations confirmed a substantial benefit in terms of lowering rates of cardiovascular events, particularly in people who had already had such an event. Unfortunately, however, despite the use of statins coupled with good-faith efforts at diet modification, many continue to be at risk of cardiovascular events because of elevated levels of LDL-C. The Need for Alternatives to Behavioral Interventions and Statins in CVD Even individuals with what were previously considered normal levels of LDL-C but also a high residual risk of recurrent CVD have been shown to benefit from further lipid lowering. The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) demonstrated that the cholesterol absorption inhibitor ezetimibe can provide additional, albeit modest, reduction of cardiovascular events when added to high-intensity statin therapy. 4 Although the use of ezetimibe in primary prevention has never been evaluated, its effect in secondary prevention is entirely consistent with predictions based on the effect of statins: a small reduction in LDL-C resulting in a small reduction in cardiovascular events. Now that multiple generic versions of ezetimibe are available, its price has dropped substantially and is now commensurate with its modest value in reducing events. The Advent of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Drugs Most recently, a scientific tour de force resulted in the development of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Over a short period, a human genetic polymorphism associated with lower low-density lipoprotein levels and lower cardiovascular event rates in epidemiological studies was translated into functional models at multiple preclinical levels, enabling target identification and the development of therapeutic molecules. The companies that won the race to develop PCSK9 inhibitors moved through development rapidly and were granted approval to market their drugs in limited populations on the basis of the demonstration of dramatic reductions in LDL-C levels without any accompanying serious toxicity. Before marketing approval, large clinical outcomes trials wer -Abstract Truncated-

An improved method for estimating low LDL-C based on the enhanced Sampson-NIH equation

Performance of the enhanced Sampson-NIH equation for VLDL-C and LDL-C in a population with familial combined hyperlipidemia

Exploring the Advantages and Limitations of the Friedewald, Martin–Hopkins, and Sampson Equations for Personalized Lipid Management

Accuracy of low-density lipoprotein cholesterol estimation at very low levels

Comparison between the Friedewald, Martin and Sampson Equations and LDL-C Quantification by Ultracentrifugation in a Mexican Population

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond

A-211 Lipids in the Afternoon: Effect on LDL-C, Triglycerides, and Collection Time When Removing Fasting Requirements for Lipid Panels

The clinical impact of estimating low-density lipoprotein cholesterol (LDL-C) using different equations in the general population

A new equation for estimating low-density lipoprotein cholesterol concentration based on machine learning

Directly Measured vs. Calculated Low-Density Lipoprotein Cholesterol Does Not Identify Additional Individuals With Coronary Artery Disease and Diabetes at Higher Risk of Adverse Events: Insight From a Large Percutaneous Coronary Intervention Cohort in Asia

Real-world efficacy of current strategies for lowering LDL cholesterol after acute coronary syndrome. Changing the treatment paradigm

Lipid Lowering Therapy and Circulating PCSK9 Concentration

Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease

Assessment of estimated low-density lipoprotein-cholesterol (LDL-c) equations: a systematic review and meta-analysis

Performance of novel low-density lipoprotein-cholesterol calculation methods in predicting clinical and subclinical atherosclerotic cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis

Balanced Dysfunction in the Healthcare Ecosystem Harms Patients.

PCSK9 inhibitors: A new era of lipid lowering therapy

A-213 Comparison of low-density lipoprotein cholesterol (LDL-c) estimates by in-lab and point-of-care devices in the context of emerging LDL-c equations

Comparison of Various Low Density Lipoprotein Cholesterol Calculators: Is It Time for the Friedewald Equation to Go in India?

The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better

Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation